Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.00, for a total value of $325,000.00. Following the completion of the sale, the insider directly owned 6,230 shares in the company, valued at $404,950. This trade represents a 44.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Corcept Therapeutics Stock Up 1.6%
NASDAQ:CORT opened at $69.49 on Friday. The stock’s 50-day simple moving average is $48.02 and its 200 day simple moving average is $52.30. The firm has a market capitalization of $7.46 billion, a PE ratio of 198.55 and a beta of 0.36. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $91.00.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The business had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $0.17 earnings per share. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 EPS for the current fiscal year.
Institutional Trading of Corcept Therapeutics
Analysts Set New Price Targets
Several analysts recently weighed in on the company. HC Wainwright raised their price objective on Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler lifted their price target on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. UBS Group set a $135.00 price target on Corcept Therapeutics in a research note on Thursday. Finally, Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.
Read Our Latest Stock Analysis on CORT
Corcept Therapeutics News Roundup
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
- Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
- Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
- Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board
Corcept Therapeutics Company Profile
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Featured Articles
- Five stocks we like better than Corcept Therapeutics
- MarketBeat Week in Review – 05/25 – 05/29
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
